Stocks · News reference

Estrella Immunopharma Activates Second Clinical Facility For Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Participants With Relapsed Or Refractory B-Cell Non-Hodgkin’s Lymphoma

Jul 29, 2026, 12:05 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 3, 2026, 12:05 PMBenzinga Newsdesk
Estrella Immunopharma Activates Third Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Trial Evaluating EB103, CD19-Redirected ARTEMIS T-Cell Therapy, In Patients With R/R B-Cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and
Read original at benzinga
ESLA
BenzingaJul 24, 2026, 12:02 PMBenzinga Newsdesk
Estrella Immunopharma Doses First Participant In Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Patients With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and
Read original at benzinga
ESLA